These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
134 related articles for article (PubMed ID: 30613662)
1. TAILORing targeted therapies to the right patient at the right time: how close are we? Zarkavelis G; Pentheroudakis G Ann Transl Med; 2018 Nov; 6(Suppl 1):S87. PubMed ID: 30613662 [No Abstract] [Full Text] [Related]
2. Primary care perspective on chronic obstructive pulmonary disease management. Make B; Belfer MH Postgrad Med; 2011 Mar; 123(2):145-52. PubMed ID: 21474902 [TBL] [Abstract][Full Text] [Related]
3. Malignant pleural mesothelioma: key determinants in tailoring the right treatment for the right patient. Wald O; Sugarbaker DJ J Thorac Dis; 2017 Mar; 9(3):485-489. PubMed ID: 28449451 [No Abstract] [Full Text] [Related]
4. Personalized medicine in oncology: tailoring the right drug to the right patient. Jiang Y; Wang M Biomark Med; 2010 Aug; 4(4):523-33. PubMed ID: 20701441 [TBL] [Abstract][Full Text] [Related]
5. Targeted therapies in breast cancer: tailoring treatment to the molecular drivers of disease progression. Hicks DG MLO Med Lab Obs; 2012 Jan; 44(1):36, 38-9. PubMed ID: 22352185 [No Abstract] [Full Text] [Related]
10. How does a new patient education programme for renal recipients become situated and adapted when implemented in the daily teaching practice in a university hospital? An ethnographic observation study. Lillehagen I; Andersen MH; Urstad KH; Wahl A; Engebretsen E BMJ Open; 2018 Nov; 8(11):e023005. PubMed ID: 30478114 [TBL] [Abstract][Full Text] [Related]
11. Treatment of sarcoidosis-associated pulmonary hypertension: A single centre retrospective experience using targeted therapies. Keir GJ; Walsh SL; Gatzoulis MA; Marino PS; Dimopoulos K; Alonso R; Raposeiras-Roubin S; Renzoni EA; Maher TM; Wells AU; Wort SJ Sarcoidosis Vasc Diffuse Lung Dis; 2014 Jul; 31(2):82-90. PubMed ID: 25078636 [TBL] [Abstract][Full Text] [Related]
12. Tailoring Medulloblastoma Treatment Through Genomics: Making a Change, One Subgroup at a Time. Holgado BL; Guerreiro Stucklin A; Garzia L; Daniels C; Taylor MD Annu Rev Genomics Hum Genet; 2017 Aug; 18():143-166. PubMed ID: 28475368 [TBL] [Abstract][Full Text] [Related]
13. Progress towards personalized medicine. Bates S Drug Discov Today; 2010 Feb; 15(3-4):115-20. PubMed ID: 19914397 [TBL] [Abstract][Full Text] [Related]
14. Metastatic HER2-Positive Breast Cancer: Tailoring Treatment Un-'TIL' We Get It Right.. Jankowitz RC; Rastogi P Oncology (Williston Park); 2016 Feb; 30(2):156, 158-9. PubMed ID: 26892152 [No Abstract] [Full Text] [Related]
15. Individualized dosing of oral targeted therapies in oncology is crucial in the era of precision medicine. Groenland SL; Mathijssen RHJ; Beijnen JH; Huitema ADR; Steeghs N Eur J Clin Pharmacol; 2019 Sep; 75(9):1309-1318. PubMed ID: 31175385 [TBL] [Abstract][Full Text] [Related]
16. Examining the boundaries of tailoring: the utility of tailoring versus targeting mammography interventions for two distinct populations. Ryan GL; Skinner CS; Farrell D; Champion VL Health Educ Res; 2001 Oct; 16(5):555-66. PubMed ID: 11675803 [TBL] [Abstract][Full Text] [Related]
17. Circulating oncoproteins HER2/neu, EGFR and CAIX (MN) as novel cancer biomarkers. Carney WP Expert Rev Mol Diagn; 2007 May; 7(3):309-19. PubMed ID: 17489737 [TBL] [Abstract][Full Text] [Related]
18. The potential variances of tailoring in health behavior interventions. Rakowski W Ann Behav Med; 1999; 21(4):284-9. PubMed ID: 10721434 [TBL] [Abstract][Full Text] [Related]
19. Targeted therapies: a new generation of cancer treatments. Gerber DE Am Fam Physician; 2008 Feb; 77(3):311-9. PubMed ID: 18297955 [TBL] [Abstract][Full Text] [Related]